Posted by Michael Wonder on 26 Jul 2017
Institute for Clinical and Economic Review announces potential topics for review in 2018
26 July 2017 - Tentative list includes drugs for migraines, haemophilia, and cystic fibrosis.
The ICER has released its preliminary list of prescription drug review topics for 2018. The list of topics for review is drawn from ICER horizon scans of new and emerging therapies, conversations with stakeholders, and suggestions submitted from the public. ICER’s topic selection criteria – including the projected timing and likelihood of FDA approval, and whether a review of the evidence would suggest specific actions for payers, physicians, patients, and policy makers to improve clinical practice and/or policy – are applied to produce a preliminary list of drugs for review.
ICER desires to time reports so that they are released as close to FDA approval as possible. Due to the time required for each report (typically 8 months), some of the drugs under consideration have not yet been submitted to the FDA for approval, but are expected to be filed in the near future. If submission plans or timing changes, alternate topics will be selected.
